EUVIMEDOpdag EUVIMED
Crossref

Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design

Yunfei Wang iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10185 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Yunfei Wang. Institution: Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA. Major MEDLINE topics: Clinical Trials, Phase I as Topic, Bayes Theorem, Maximum Tolerated Dose, Dose-Response Relationship, Drug. 27 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Dual‐agent treatment has become more and more popular in clinical trials. We have developed an approach called rapid enrollment dual‐agent design (REDD) for dose‐finding in Phase I clinical trials. This approach aims to administer treatment to patients using a dose combination that is highly probable to be the target dose combination. Unlike other non‐model‐based designs, rapid enrollment designs (RED and REDD) do not require waiting for all patients to complete an assessment before the assignment of the next participant. Simulations showed that across several scenarios, the average performance of REDD is comparable to that of the Bayesian optimal interval (BOIN) design and the partial order continual reassessment method (POCRM). The simulation results of REDD for late‐onset toxicity assessments demonstrated that assigning patients to a dose combination as they are being enrolled, without waiting for the most recent cohort of patients to complete their follow‐up, does not significantly compromise the quality of the maximum tolerated dose (MTD) estimation. Instead, it saves a considerable amount of time in clinical trial enrollment. User‐friendly online applications have also been created to further facilitate the adoption of rapid enrollment designs in Phase I trials. In summary, being similar to BOIN and POCRM in performance, REDD is an approach that is easily comprehensible, straightforward to implement and offers an advantage of enrolling patients without having to wait for all current patients to complete their follow‐ups for toxicity.

Subjects

MeSH terms (MEDLINE)

Clinical Trials, Phase I as TopicBayes TheoremMaximum Tolerated DoseDose-Response Relationship, DrugComputer SimulationHumansResearch DesignAntineoplastic Combined Chemotherapy ProtocolsPatient Selection

Author keywords

Bayesian optimal interval designdose‐findingpartial order continual reassessment methodrapid enrollment dual‐agent design (REDD)

Authors and institutions

  • Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID profiles: Yunfei Wang

Cite

APA

Wang, Y. (2024). Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design. Statistics in Medicine. https://doi.org/10.1002/sim.10185

Vancouver

Wang Y. Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design. Statistics in Medicine. 2024. doi:10.1002/sim.10185

BibTeX
@article{Wang2024,
  author = {Wang, Yunfei},
  title = {Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10185}
}
Start for free →